Semaglutide biosimilar(Beijing QL Biopharm)

司美格鲁肽生物类似药（北京质肽生物）

Report date: 2025/09/11 15:51:34

Base Information

Drug NameSemaglutide biosimilar(Beijing QL Biopharm)
Drug Alias Namesemaglutida biosimilar索马鲁肽生物类似药semaglutidum biosimilar索玛鲁肽生物类似药司美鲁肽生物类似药 +[10] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsOverweightObesityDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesBeijing QL Biopharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Aimeike Technology Development Co LtdBeijing QL Biopharmaceutical Co LtdBeijing Nuobot Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsOverweightObesityDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A